Who
Shawn Cross
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Pacira BioSciences; Director, Cyclo Therapeutics; CEO & Chair of the Board, Applied Molecular Transport.
In numbers
- Trades disclosed
- 76
- Buys
- 0
- Sells
- 19
- Bought
- $0
- Sold
- $2.5M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 1 Mar 2021
- Last trade
- 23 Apr 2026
- Last filed
- 24 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Apr 2026filed 24 Apr 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code M | $213K12,941 at $16.45 | filing |
| 23 Apr 2026filed 24 Apr 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $326K12,941 at $25.16 | filing |
| 23 Apr 2026filed 24 Apr 2026 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —12,941 at $0.00 | filing |
| 23 Apr 2026filed 24 Apr 2026 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —12,941 at $0.00 | filing |
| 23 Apr 2026filed 24 Apr 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code M | $213K12,941 at $16.45 | filing |
| 23 Apr 2026filed 24 Apr 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $326K12,941 at $25.16 | filing |
| 22 Apr 2026filed 22 Apr 2026 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,500 at $0.00 | filing |
| 22 Apr 2026filed 22 Apr 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code M | $25K1,500 at $16.45 | filing |
| 22 Apr 2026filed 22 Apr 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $38K1,500 at $25.01 | filing |
| 22 Apr 2026filed 22 Apr 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code M | $25K1,500 at $16.45 | filing |
| 22 Apr 2026filed 22 Apr 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $38K1,500 at $25.01 | filing |
| 22 Apr 2026filed 22 Apr 2026 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,500 at $0.00 | filing |
| 21 Apr 2026filed 22 Apr 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code M | $47K2,845 at $16.45 | filing |
| 21 Apr 2026filed 22 Apr 2026 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,845 at $0.00 | filing |
| 21 Apr 2026filed 22 Apr 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $71K2,845 at $25.01 | filing |
| 21 Apr 2026filed 22 Apr 2026 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,845 at $0.00 | filing |
| 21 Apr 2026filed 22 Apr 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code M | $47K2,845 at $16.45 | filing |
| 21 Apr 2026filed 22 Apr 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $71K2,845 at $25.01 | filing |
| 20 Apr 2026filed 22 Apr 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code M | $127K7,714 at $16.45 | filing |
| 20 Apr 2026filed 22 Apr 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $194K7,714 at $25.14 | filing |
News
Pacira BioSciences (NASDAQ:PCRX) Upgraded at JPMorgan Chase & Co.PCRX · themarketsdaily.com · 11 Oct 2026Insider Selling: Pacira BioSciences (NASDAQ:PCRX) SVP Sells $217,920.00 in StockPCRX · themarketsdaily.com · 10 Oct 2026Pacira BioSciences jumps 44% on Viatris acquisition deal (PCRX:NASDAQ)PCRX · seekingalpha.com · 8 Oct 2026
0 headlines in the last 90 days name Shawn Cross; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.